News|Articles|October 26, 2025
Day 3 Recap: Fall Clinical 2025
Listen
0:00 / 0:00
Key Takeaways
- Socioeconomic status impacts access to advanced psoriasis therapies, with disadvantaged patients less likely to receive biologic or small molecule treatments.
- Emerging skin treatments, including biologics and JAK inhibitors, present unique clinical challenges for clinicians.
Catch up on coverage from the third day of the 2025 Fall Clinical Dermatology Conference held in Las Vegas, Nevada.
Advertisement
To stay informed with the latest conference insights, follow us on social media and
Socioeconomic Status Shapes Access to Advanced Psoriasis Therapies
New data presented at Fall Clinical 2025 reveal that patients in socioeconomically disadvantaged areas are significantly less likely to initiate biologic or small molecule treatments.
Navigating Biologics and JAK Inhibitors with James Del Rosso, DO
Emerging skin treatments present unique clinical challenges that must be anticipated by clinicians.
From 30 Tips to 3 Key Insights from 3 Experts
Discover essential dermatology insights from experts at the Fall Clinical Conference 2025, featuring innovative treatment tips and patient care strategies.
Exploring the OX40 Ligand Pathway and Chronic Itch
At Fall Clinical 2025, Shawn Kwatra, MD, presented insights on managing various cases of chronic itch, as well as understanding the OX40 ligand pathway as the “prequel to inflammation.”
Christopher Bunick, MD, PhD, Highlights JAK Inhibitors in AD Care
Clinicians are now aiming for treatment targets such as NRS 0–1, IGA 0–1, and EASI 90 to define successful AD management.
Our editors are on site and ready to gather your insights, both as a presenter or as an attendee! Reach out to us at
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Improving Outcomes in Acne, Hidradenitis Suppurativa, and Vitiligo Through Treatment Advancements
2
Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years
3
Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline
4
AEON's ABP-450 Achieves Critical Analytical Milestone, Demonstrating High Biosimilarity to BOTOX
5
